Teleflex Incorporated (NYSE:TFX) Receives $252.50 Consensus Price Target from Analysts

Teleflex Incorporated (NYSE:TFX) has earned a consensus recommendation of “Moderate Buy” from the seven research firms that are presently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $252.50.

A number of analysts have commented on the stock. Truist Financial cut their price objective on shares of Teleflex from $227.00 to $200.00 and set a “hold” rating for the company in a report on Wednesday, December 18th. Needham & Company LLC reiterated a “hold” rating on shares of Teleflex in a research report on Monday, December 16th. Mizuho dropped their target price on Teleflex from $275.00 to $250.00 and set a “neutral” rating for the company in a report on Friday, November 1st. Royal Bank of Canada cut their target price on Teleflex from $275.00 to $245.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Finally, StockNews.com raised shares of Teleflex from a “hold” rating to a “buy” rating in a research report on Thursday, November 28th.

Teleflex Price Performance

Shares of Teleflex stock opened at $180.95 on Friday. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.42 and a quick ratio of 1.39. The business has a 50 day simple moving average of $182.85 and a two-hundred day simple moving average of $214.37. The stock has a market capitalization of $8.40 billion, a P/E ratio of 35.97, a PEG ratio of 1.79 and a beta of 1.16. Teleflex has a 12 month low of $171.69 and a 12 month high of $256.85.

Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, October 31st. The medical technology company reported $3.49 EPS for the quarter, beating the consensus estimate of $3.38 by $0.11. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. The firm had revenue of $764.40 million during the quarter, compared to the consensus estimate of $768.68 million. During the same period in the prior year, the company earned $3.64 EPS. The firm’s revenue was up 2.4% compared to the same quarter last year. As a group, analysts predict that Teleflex will post 13.98 EPS for the current fiscal year.

Teleflex Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Friday, November 15th were paid a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.75%. The ex-dividend date of this dividend was Friday, November 15th. Teleflex’s dividend payout ratio (DPR) is 27.04%.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC boosted its holdings in Teleflex by 84.7% during the 2nd quarter. Acadian Asset Management LLC now owns 399 shares of the medical technology company’s stock valued at $83,000 after acquiring an additional 183 shares during the period. American Century Companies Inc. grew its holdings in shares of Teleflex by 4.6% in the second quarter. American Century Companies Inc. now owns 9,509 shares of the medical technology company’s stock valued at $2,000,000 after purchasing an additional 420 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in Teleflex by 2.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 57,946 shares of the medical technology company’s stock worth $12,188,000 after buying an additional 1,221 shares during the period. Dimensional Fund Advisors LP boosted its position in Teleflex by 4.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 398,175 shares of the medical technology company’s stock valued at $83,741,000 after buying an additional 15,992 shares during the period. Finally, Edgestream Partners L.P. purchased a new position in Teleflex in the 2nd quarter valued at approximately $350,000. 95.62% of the stock is currently owned by institutional investors and hedge funds.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.